Effect of Withania somnifera (Ashwagandha) on the Development of Chemotherapy-Induced Fatigue and Quality of Life in Breast Cancer Patients
Effect of Withania somnifera (Ashwagandha) on the Development of Chemotherapy-Induced Fatigue and Quality of Life in Breast Cancer Patients
复制标题
DOI：
10.1177/1534735412464551
复制
发表时间：
2013-07-01
影响因子：
2.9
通讯作者：
Musa, Kamarul Imran
中科院分区：
文献类型：
--
作者：
Biswal, Biswa Mohan;Sulaiman, Siti Amrah;Musa, Kamarul Imran
假设。 Withania somnifera 是一种具有抗氧化、抗炎、抗癌、抗应激和适应原特性的草本植物。先前的研究已显示其对动物的抗应激作用。几个世纪以来，印度传统医学一直使用它来缓解疲劳和改善整体健康。方法。这是一项开放标签前瞻性非随机比较试验，受试者为 100 名各个阶段的乳腺癌患者，这些患者接受化疗与口服睡茄联合治疗或单独化疗。化疗方案为泰索帝、阿霉素和环磷酰胺或5-氟尿嘧啶、表阿霉素和环磷酰胺。在整个化疗过程中，研究组患者每 8 小时服用 2 g 睡茄根提取物。使用 EORTC QLQ-C30（第 3 版）、Piper 疲劳量表 (PFS) 和 Schwartz 癌症疲劳量表 (SCFS-6) 评估化疗前、化疗期间和最后一个周期的生活质量和疲劳评分。结果。研究组和对照组的中位年龄分布分别为 51 岁（范围 = 36-70）和 50.5 岁（范围 = 32-71）。大多数（77%）患者患有 II 期和 III 期疾病。与研究组相比，对照组患者的疲劳评分边际均值估计值显着较高（P < .001 PFS，P < .003 SCFS-6）。此外，与对照组相比，干预组 18 种症状中有 7 种 EORTC QLQ-C30 的各种症状量表具有统计学显着性 (P < .001)。研究组和对照组患者各阶段的 24 个月总生存率分别为 72% 和 56%；然而，中位随访时间为 26 个月，结果并不显着 (P = .176)。结论。除了提高生活质量之外，睡茄还具有对抗癌症相关疲劳的潜力。然而，有必要在随机试验中进行更大样本量的进一步研究来验证我们的研究结果。
Hypothesis. Withania somnifera is an herb with antioxidant, anti-inflammatory, anticancer, antistress, and adaptogenic properties. Previous studies have shown its antistress effects in animals. Traditional Indian medicine has used it for centuries to alleviate fatigue and improve general well-being. Methods. This is an open-label prospective nonrandomized comparative trial on 100 patients with breast cancer in all stages undergoing either a combination of chemotherapy with oral Withania somnifera or chemotherapy alone. The chemotherapy regimens were either taxotere, adriamycin, and cyclophosphamide or 5-fluorouracil, epirubicin, and cyclophosphamide. Withania somnifera root extract was administered to patients in the study group at a dose of 2 g every 8 hours, throughout the course of chemotherapy. The quality-of-life and fatigue scores were evaluated before, during, and on the last cycles of chemotherapy using the EORTC QLQ-C30 (Version 3), Piper Fatigue Scale (PFS), and Schwartz Cancer Fatigue Scale (SCFS-6). Results. The median age distributions in the study and control arm were 51 years (range = 36-70) and 50.5 years (range = 32-71), respectively. The majority (77%) of patients had stage II and III disease. Patients in the control arm experienced statistically significant higher estimated marginal means of fatigue score compared with the study group (P < .001 PFS, P < .003 SCFS-6). Furthermore, various symptom scales of the EORTC QLQ-C30 were statistically significant in 7 out of 18 symptoms in the intervention group compared with the control group (P < .001). The 24-month overall survival for all stages in study and control group patients were 72% versus 56%, respectively; however, the result was not significant (P = .176), at a median follow-up duration of 26 months. Conclusions. Withania somnifera has potential against cancer-related fatigue, in addition to improving the quality of life. However, further study with a larger sample size in a randomized trial is warranted to validate our findings.